Please login to the form below

Not currently logged in
Email:
Password:

Roche to publish data

Roche has become the latest pharmaceutical company to set up its own clinical trials database.

Roche has become the latest pharmaceutical company to set up its own clinical trials database.

The Swiss pharma company said that it would establish a clinical trials database to display key results from completed clinical trials. This, Roche said, would ensure fair reporting of all Roche-sponsored trials that might affect the practice of medicine.

Links to a global registry and database, local registries and references to results published in scientific journals will also be included in the database.

In addition, a clinical trials protocol registry will be created to provide information on phase II to phase IV trials before they are conducted. The registry is expected to include information in layman's terms on all the trials so that patients can understand their purpose and conditions.

Data posted on the sites will include any phase II-IV trial completed on or after October 1, 2004 and for products marketed on or after October 2, 2002.

Roche hopes the sites will be hosted by an independent organisation and be available by the end of the first quarter of 2005.

Ed Holdener, head of global pharma development at Roche said: ìTransparency on the results of its clinical studies has always been important to Roche. At the same time, it is important that we protect the safety and the rights of patients and secure the quality and integrity of the data and related conclusions.

ìOur current policy on the publication of clinical trial data will be further enhanced and consolidated by the creation of one electronic source of information. This clear and transparent approach is in the best interest of all parties involved,î he added.

Roche's decision to publish its results follows an initiative agreed earlier this month by a group of pharmaceutical associations to make all clinical trial data freely available. It is hoped the measure will go some way to ensuring greater transparency following recent media reports concerning the safety of well-known drugs.

The Association of the British Pharmaceutical Industry, GlaxoSmithKline and Eli Lilly & Company have already set up their own databases.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics